In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.
Markets Take A Pause; Stock Setups Continue.
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Is (INCY) Outperforming Other Medical Stocks This Year?
Biotech Stock Outlook: M&A Activity Retains Growth Streak
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Moving Average Crossover Alert: Incyte

05:13am, Tuesday, 10'th Dec 2019
Incyte is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

9 Most Overbought Stocks In The S&P 500

10:35am, Monday, 09'th Dec 2019
While value investors look for stocks that have become priced too low or high based on fundamental metrics such as earnings, revenue and debt, technical traders base their buys and sells off of recent
Incyte's NDA For Pemigatinib Drug Accepted, But It Is Not A One Hit Wonder

Why Incyte Stock Climbed 12.2% in November

09:56am, Wednesday, 04'th Dec 2019
Strong sales for the company's main drug and potential new applications and treatments have pushed the pharma stock up 48% in 2019.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post Looking For Growth?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Nasdaq, S&P 500 soar to new highs; Alibaba, Splunk, Incyte break out.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE